MA-PATHAI
21.5.2024 09:01:26 CEST | Business Wire | Press release
PathAI, a global leader in AI-powered pathology, today announced a new Early Access Program (EAP) to drive adoption of its AISightTM Image Management System (IMS) in Mainland Europe.1 Earlier in 2023, PathAI announced a similar program for laboratories in the United States, which attracted over 50 laboratories with many exploring long-term use of PathAI’s AISight Image Management System and broad menu of AI Products.
As part of the EAP, AP Laboratories in Europe can trial AISight, a modern and cloud-based digital pathology solution compliant with GDPR, as well as conduct and publish real-world validation studies of PathAI’s AI Products such as ArtifactDetect, TumorDetect, AIM-TumorCellularity, AIM-PD-L1, and AIM-HER2.2
“We are thrilled to commence a more dedicated focus to bring AISight Image Management System to labs in Europe. We have continued to make improvements on the platform with input from our first set of commercial customers in the U.S. We are excited to partner with European labs in democratizing access to digital pathology, enhancing pathologist experience, and ultimately improving patient outcomes,” said Nick Brown, Chief Growth Officer at PathAI.
AISight is a cloud-based platform that enables efficient end-to-end digital pathology workflows. AISight provides best-in-class caseload balancing and assignment, caselist prioritization, image ingestion, image viewing, collaboration tools, and image and case management. Via AISight Link, AISight can also be integrated bidirectionally with laboratory information systems for streamlined workflows. Anatomic pathology laboratories of all sizes and specialties – including health systems, university hospitals, and reference laboratories – may utilize AISight.
“PathAI has been an excellent thought partner for helping our institution think through what it means to create a modern, next-generation digital pathology workflow that spans versatile use cases like research, clinical trials, and diagnostics,” said Prof. Dr. Jan Budczies, Head of Medical Bioinformatics at the University of Heidelberg. “We are excited to partner with PathAI on this Early Access Program and look forward to taking advantage of their growing portfolio of features and algorithms on AISight, starting with our Molecular Pathology Department where we are especially interested in understanding the feasibility of estimating tumor cell content and characterizing immune cell infiltrates more precisely by leveraging digital pathology and artificial intelligence.”
AISight enables pathologists with seamless access to a broad array of algorithms to drive workflow optimization, standardized biomarker quantitation, and next-generation case prioritization including ArtifactDetect, TumorDetect, AIM-TumorCellularity, AIM-PD-L1 (NSCLC, HNSCC, Melanoma, Urothelial), and AIM-HER2 Breast Cancer and will also host third-party algorithms on request.
“We have trialed AISight at our department for several months now. At our Molecular Pathology Unit we are especially interested in understanding the feasibility of estimating tumor cell content through image analysis. PathAI’s AIM-TumorCellularity can be a tool that will change time to treatment for patients in need of molecular testing,” said Prof. Dr. Holger Moch, Director of Pathology at the University of Zurich and PathAI Advisor. “PathAI has been responsive to our unique needs and a valuable thought partner in helping us think through how to pick the most modern and innovative digital pathology solution on the market. We are excited about our partnership with PathAI and look forward to taking advantage of their growing portfolio of algorithms and feature improvements on AISight.”
“We have been leveraging the AIM-PD-L1 NSCLC and AIM-TumorCellularity NSCLC Algorithms over the past few months at our institution as part of a large research cohort,” said Dr. Jose Palacios, Director of Pathology at Ramon y Cajal Hospital in Madrid, Spain. “Given the success we’ve seen at our own institution, there has been increasing demand from across Spain to leverage these algorithms and we are working with more than 10+ hospitals across Spain to implement these tools.”
PathAI expects IVDR Certification of AISight Dx for primary diagnosis by Q3 2024. Early Access Program Participants will be the first to receive access to this platform. To learn more about AISight, visit our website. PathAI’s team will also be at upcoming conferences including the European Congress of Digital Pathology in Vilnius, Lithuania (June 5-8), European Congress of Pathology in Florence, Italy (September 7-11), and the DP/AI Congress in London, United Kingdom (December 7-8).
Footnotes
1 AISight™ is for research use only. Not for use in diagnostic procedures.
2 ArtifactDetect™, TumorDetect™, AIM-TumorCellularity™, AIM-PD-L1™ and AIM-HER2™ are research use only. Not for use in diagnostic procedures.
About PathAI
PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases.
PathAI is headquartered in Boston, MA. For more information, please visit www.pathai.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521660078/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom